Clinical Rheumatology

, Volume 16, Issue 4, pp 354–360 | Cite as

The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: A four-year study

  • G. P. Lyritis
  • N. Tsakalakos
  • I. Paspati
  • Gr. Skarantavos
  • A. Galanos
  • C. Androulakis


To develop an improved treatment schedule for osteoporosis, a study was undertaken in 100 postmenopausal women using a modified ADFR 90-day cyclical regimen with etidronate. After one year of treatment, the etidronate-treated group showed a significant increase in bone density of the spine, which continued over the following 2 years of treatment and remained stable during the fourth year. In contrast, in the non-etidronate group, bone density decreased significantly after four years. In addition, the fracture rate was significantly lower in the etidronate group than in the non-etidronate group. Side effects were minimal in both groups and no serious adverse reactions were reported. In conclusion, it appears that a cyclical regimen using 1,25-dihydroxyvitamin D3, etidronate and calcium increases bone mass and reduces fractures with no significant side effects, thus making a useful contribution in the treatment of postmenopausal osteoporosis.

Key words

Bone Mineral Density Etidronate 1,25-dihydroxyvitamin D3 Postmenopausal Osteoporosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arlot ME, Delmas PE, Meunier PJ. Trabecular and cortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal women. Osteoporosis Int 1990; 1: 41–9.Google Scholar
  2. 2.
    Watts N, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata Ross P, Woodson III GC, Yanover MJ, Misiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chestnut III CH. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9.Google Scholar
  3. 3.
    Rico H, Hernandez ER, Revilla M, Gomez-Castrasana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992; 16: 131–8.Google Scholar
  4. 4.
    Kanis JA, Johnell O, Guilberg B, Allander E, Dilsen G, Gennari C, Vaz AAL, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Cano RP, Rapado A, Ribot C. Evidence for efficacy of drugs effecting bone metabolism in preventing hip fracture. Br Med J 1992; 305: 1124–8.Google Scholar
  5. 5.
    Lyritis G, Marketou H, Magiasis B, Dracopoulos D, Tsekoura M, Tsakalakos N, Yiatzides A. Estimation of postmenopausal bone loss with the use of biochemical bone markers. Bone Miner 1992; 17, Suppl. 1: 154.Google Scholar
  6. 6.
    Garnero P, Sornan-Rendu E, Chapuy MC, Delmas P. Increased bone turnover in late postmenopausal women. Is a major determonant of osteoporosis? J Bone Miner Res 1996; 11: 337–49.Google Scholar
  7. 7.
    Civitelli R, Gonelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. Bone turnover in postmenopausal osteoporosis. Effects of calcitonin treatment. J Clin Invest 1988; 82: 1268–74.Google Scholar
  8. 8.
    Frost HM. The ADFR concept and monitoring it. Metab Bone Dis Related Res 1980; 2, Suppl: 317–21.Google Scholar
  9. 9.
    Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Miner 1989; 5: 201–12.Google Scholar
  10. 10.
    Lyritis GP, Tsakalakos N, Karachalios T, Magiasis B, Athanasopoulou E, Androulakis K, Tsekoura M, Hatziolou E, Yatzides A, Gazi S. Treatment of postmenopausal osteoporosis with the ADFR regimen. Calcif Tissue Int 1989, 44 Suppl. 1: 68.Google Scholar
  11. 11.
    Pacifici R, McMurthy C, Veder I, Rupich R, Avioli LV. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metabol 1988; 66: 747–53.Google Scholar
  12. 12.
    Passeri M, Palumeri E, Barbagallo M, Buttirini L, Pedrazzoni M, Davoli L, Pioli G, Benassi L, Girasole G, Ciotti G. Sequential calcitriol-calcitonin in the therapy of osteoporosis. Minerva Endocrinol 1989; 14: 57–62.Google Scholar
  13. 13.
    Behrens-Stevens ML, Wagenknecht R, Haberey M. The effects of high dose calcitriol on rat bone. Bone Miner 1992; 17, Suppl. 1: 109.Google Scholar
  14. 14.
    Storm T, Thamsborg G, Dteinich T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71.Google Scholar
  15. 15.
    Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chstnut III CH. Four-year study of intermittent cyclic etidtronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557–67.Google Scholar
  16. 16.
    Aloia JF, Waswani A, Yeh JK et al. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988; 84: 4018.Google Scholar

Copyright information

© Clinical Rheumatology 1997

Authors and Affiliations

  • G. P. Lyritis
    • 1
  • N. Tsakalakos
    • 1
  • I. Paspati
    • 1
  • Gr. Skarantavos
    • 1
  • A. Galanos
    • 1
  • C. Androulakis
    • 1
  1. 1.Laboratory for the Research of Musculoskeletal SystemUniversity of Athens, KAT HospitalAthensGreece

Personalised recommendations